343 related articles for article (PubMed ID: 15203275)
1. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.
Pardanani A; Kimlinger T; Reeder T; Li CY; Tefferi A
Leuk Res; 2004 Aug; 28(8):777-83. PubMed ID: 15203275
[TBL] [Abstract][Full Text] [Related]
2. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders.
Sánchez-Muñoz L; Teodósio C; Morgado JM; Escribano L
Methods Cell Biol; 2011; 103():333-59. PubMed ID: 21722810
[TBL] [Abstract][Full Text] [Related]
3. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
4. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults.
Escribano L; Díaz Agustín Beatriz ; Bravo P; Navalón R; Almeida J; Orfao A
Leuk Lymphoma; 1999 Oct; 35(3-4):227-35. PubMed ID: 10706445
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis.
van Daele PL; Beukenkamp BS; Geertsma-Kleinekoort WM; Valk PJ; van Laar JA; van Hagen PM; van der Velden VH
Neth J Med; 2009 Apr; 67(4):142-6. PubMed ID: 19581658
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
7. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.
Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R
Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905
[TBL] [Abstract][Full Text] [Related]
8. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
[TBL] [Abstract][Full Text] [Related]
9. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry.
Baumgartner C; Sonneck K; Krauth MT; Kneidinger M; Födinger M; Hauswirth AW; Müllauer L; Valent P
Eur J Clin Invest; 2008 May; 38(5):326-35. PubMed ID: 18363719
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA).
Escribano L; Diaz-Agustin B; López A; Núñez López R; García-Montero A; Almeida J; Prados A; Angulo M; Herrero S; Orfao A;
Cytometry B Clin Cytom; 2004 Mar; 58(1):1-8. PubMed ID: 14994369
[TBL] [Abstract][Full Text] [Related]
12. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry.
Chisholm KM; Merker JD; Gotlib JR; Gitana G; Lefterova M; Zehnder JL; George TI; Arber DA; Ohgami RS
Am J Clin Pathol; 2015 Apr; 143(4):527-34. PubMed ID: 25780004
[TBL] [Abstract][Full Text] [Related]
13. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis.
Hollmann TJ; Brenn T; Hornick JL
Am J Surg Pathol; 2008 Jan; 32(1):139-45. PubMed ID: 18162781
[TBL] [Abstract][Full Text] [Related]
14. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
15. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry.
Bodni RA; Sapia S; Galeano A; Kaminsky A
J Eur Acad Dermatol Venereol; 2003 Mar; 17(2):160-6. PubMed ID: 12705744
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric immunophenotypic analysis of systemic mastocytosis involving bone marrow.
Jabbar KJ; Medeiros LJ; Wang SA; Miranda RN; Johnson MR; Verstovsek S; Jorgensen JL
Arch Pathol Lab Med; 2014 Sep; 138(9):1210-4. PubMed ID: 25171703
[TBL] [Abstract][Full Text] [Related]
17. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.
Morgado JM; Perbellini O; Johnson RC; Teodósio C; Matito A; Álvarez-Twose I; Bonadonna P; Zamò A; Jara-Acevedo M; Mayado A; Garcia-Montero A; Mollejo M; George TI; Zanotti R; Orfao A; Escribano L; Sánchez-Muñoz L
Histopathology; 2013 Dec; 63(6):780-7. PubMed ID: 24111625
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
Hahn HP; Hornick JL
Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
[TBL] [Abstract][Full Text] [Related]
19. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
[TBL] [Abstract][Full Text] [Related]
20. Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis.
Cherian S; McCullouch V; Miller V; Dougherty K; Fromm JR; Wood BL
Cytometry B Clin Cytom; 2016 Jul; 90(4):387-92. PubMed ID: 26525770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
